Momenta Pharmaceuticals, Inc. (NASDAQ: MNTA) focuses its efforts on leveraging its proprietary technology to discover the structural secrets of complex sugars and other complex mixtures. The company’s novel approach to drug development and innovative tools have yielded a diversified product pipeline containing technology-enabled generic drugs, re-engineered drugs and novel drug candidates. Momenta’s strategic objective is to create near-term revenue opportunities that will fund longer-term discovery and development. For further information, visit the Company’s web site at www.momentapharma.com.
- 17 years ago
QualityStocks
Momenta Pharmaceuticals, Inc. (NASDAQ: MNTA)
Tags Rodman & Renshaw
Related Post
-
QualityStocksNewsBreaks – Onar Holding Corporation (OTCQB: ONAR) Details Board Additions, AI Partnerships and M&A Moves
Onar (OTCQB: ONAR), a marketing technology company and global network of performance-driven agencies, issued a…
-
QualityStocksNewsBreaks – Vision Marine Technologies Inc. (NASDAQ: VMAR) Sees 504% Boat Sales Surge, Slashes Debt Following Nautical Ventures Acquisition
Vision Marine Technologies (NASDAQ: VMAR), a leader in electric marine propulsion and multi-brand boat…
-
Ucore Rare Metals Inc. (TSX.V: UCU) (OTCQX: UURAF) Secures $18.4M DoD Award to Fast-Track Heavy Rare Earth Independence
This phase 2 award builds on phase 1 success, during which Ucore successfully separated two heavy…